Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other ...

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...

Multiple myeloma patients with COVID-19 have high rates of hospitalization, ICU admission, and death, according to researchers.

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin and lead ...

Patti Scialfa, Bruce Springsteen’s wife, recently shared that she was diagnosed in 2018 with a type of blood cancer known as ...

The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.